Literature DB >> 1337262

Psoriasis treatment with vitamin D derivatives.

T Menné1, K Larsen.   

Abstract

The naturally occurring 1,25(OH)2 vitamin D3 and the two synthetic derivatives 1,24(OH)2 vitamin D3 and calcipotriol (Calcipotriol, INN, Calcipotriene, USAN) have a profound effect on keratinocyte proliferation and differentiation. Clinical trials have shown an effect of all three derivatives in psoriasis. The limiting factor for the use of 1,25(OH)2 vitamin D3 is the risk of hypercalcemia, which is 100 to 200 times less for calcipotriol and that may be less also for 1,24(OH)2 vitamin D3. Presently, calcipotriol in an ointment base has been marketed in a number of countries and represents an alternative to treatment with topical glucocorticoids and dithranol.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1337262

Source DB:  PubMed          Journal:  Semin Dermatol        ISSN: 0278-145X


  4 in total

Review 1.  Tacalcitol.

Authors:  D C Peters; J A Balfour
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.

Authors:  M Seyger; W Abramovits; M Liljedahl; M N Hoejen; J Teng
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-02-19       Impact factor: 6.166

3.  Effects of recombinant human parathyroid hormone (1-34)on cell proliferation, chemokine expression and the Hedgehog pathway in keratinocytes.

Authors:  Xiaolin Bu; Xinling Bi; Wuqing Wang; Yuling Shi; Qiang Hou; Jun Gu
Journal:  Mol Med Rep       Date:  2018-02-07       Impact factor: 2.952

4.  Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial.

Authors:  L F Eichenfield; D Marcoux; M Kurvits; M Liljedahl
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-01-02       Impact factor: 6.166

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.